GGrantIndex
Sort

40,608 grants matching prostate cancer

Virginia-UCLA-Toronto Biomarker Characterization Center

$664,127
Oliver John Semmes · Eastern Virginia Medical School · U2C · FY2022 · CA

Small Molecule ERG Inhibitors for Prostate Cancer

$664,086
John Hackett Bushweller · University Of Virginia · R01 · FY2025 · CA

Role of HSP90 Family Chaperone Proteins in Cellular Signal Transduction

$663,995
Leonard Neckers · Division Of Clinical Sciences - Nci · Z01 · FY2008 · CA

Pathway-guided treatment of immune checkpoint inhibitor therapy-induced colon toxicity

$663,989
Jennifer D Wu · Northwestern University At Chicago · R01 · FY2025 · CA

Pathway-guided treatment of immune checkpoint inhibitor therapy-induced colon toxicity

$663,989
Jennifer D Wu · Northwestern University At Chicago · R01 · FY2023 · CA

Comprehensive characterization of prostate stromal gene expression and association with lethal prostate cancer

$663,895
Kathryn L Penney · Brigham And Women'S Hospital · R37 · FY2019 · CA

Modeling Best Approaches for Cardiovascular Disease Prevention in Cancer Survivors

$663,802
Juan P Wisnivesky · Icahn School Of Medicine At Mount Sinai · R01 · FY2024 · CA

Magneto-Nano Protein Chip and Multiplex Sorter for Monitoring Tumor Markers

$663,785
Shan X. Wang · Stanford University · U54 · FY2008 · CA

Software to facilitate multimode, multiscale fused data for Pathology and Radiolo

$663,749
Michael D Feldman · University Of Pennsylvania · R01 · FY2010 · CA

Improving Patient-Important Outcomes with Testosterone Replacement in Hypogonadal Men with a Prior History of Cancer

$663,748
Jose M. Garcia · Seattle Inst For Biomedical/Clinical Res · R01 · FY2020 · CA

Multimodal MR-PET Machine Learning Approaches for Primary Prostate Cancer Characterization

$663,746
Ciprian Catana · Massachusetts General Hospital · R01 · FY2019 · CA

Development of Protein Degraders Targeting EZH2 Non-enzymatic Functions in Prostate Cancer

$663,713
Jindan Yu · Emory University · R01 · FY2024 · CA

Image guided intervention system for pancreatic cystic lesions

$663,707
Nicusor Iftimia · Physical Sciences, Inc · R44 · FY2010 · CA

Tulane Medical/Cancer Center Minority-Based Community Clinical Oncology Program

$663,700
William Russell Robinson · Tulane University Of Louisiana · U10 · FY2013 · CA

Angiotensin II Receptors And Signaling Mechanisms

$663,660
Kevin J Catt · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2009 · HD

Metabolic Mechanisms for Programmed Cell Death

$663,560
James M Phang · Division Of Basic Sciences - Nci · Z01 · FY2008 · CA

Cell free nucleic acid-based biomarkers in advanced prostate cancer

$663,505
Liang Wang · Medical College Of Wisconsin · R01 · FY2017 · CA

Data Processing, Analysis and Modeling Unit

$663,501
Jeremy Goecks · Oregon Health & Science University · U2C · FY2021 · CA

Use and Outcomes of Radiation Therapy for Medicare Patients with Common Cancers

$663,470
Cary P Gross · Yale University · R01 · FY2010 · CA

Clinical Trial of Vitamin D3 to Reduce Cancer Risk in Postmenopausal Women

$663,406
Joan M Lappe · Creighton University · R01 · FY2013 · CA

Proactive Outreach and Streamlined Genetic Testing in Prostate Cancer Survivors

$663,383
Marc D Schwartz · Georgetown University · R01 · FY2025 · CA

Combining immunotherapy with molecularly targeted radiation therapy

$663,343
Lawrence Fong · University Of California, San Francisco · R01 · FY2023 · CA

Platelets in Cancer

$663,334
Tatiana V Byzova · Cleveland Clinic Lerner Com-Cwru · R01 · FY2021 · HL

Platelets in Cancer

$663,334
Tatiana V Byzova · Cleveland Clinic Lerner Com-Cwru · R01 · FY2020 · HL

Screening for Free: A Value-Based Insurance Design Natural Experiment

$663,309
John Hsu · Massachusetts General Hospital · R01 · FY2012 · CA